Cutaneous Events Associated with Immunotherapy of Melanoma: A Review
Lorenza Burzi, Aurora Alessandrini, Pietro Quaglino, Bianca Maria Piraccini, Emi Dika, Simone Ribero
Abstract
Immunotherapy with checkpoint inhibitors significantly improves the outcome for stage III and IV melanoma. Cutaneous adverse events during treatment are often reported. We herein aim to review the principal pigmentation changes induced by immune check-point inhibitors: the appearance of vitiligo, the Sutton phenomenon, melanosis and hair and nail toxicities.
Topics & Concepts
MedicineVitiligoDermatologyMelanomaImmunotherapyAdverse effectNail (fastener)Immune systemOncologyImmunologyInternal medicineCancer researchMaterials scienceMetallurgyMelanoma and MAPK PathwaysCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses